• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ELI LILLY AND COMPANY HUMAPEN LUXURA HALF-DOSE PEN; FOR TREATMENT PURPOSES

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ELI LILLY AND COMPANY HUMAPEN LUXURA HALF-DOSE PEN; FOR TREATMENT PURPOSES Back to Search Results
Model Number MS9673A
Device Problems Break (1069); Detachment Of Device Component (1104)
Patient Problem Hyperglycemia (1905)
Event Date 05/31/2018
Event Type  Injury  
Manufacturer Narrative
If device is returned, evaluation will be performed to determine if a malfunction has occurred.A follow-up report will be submitted when the final evaluation is completed as necessary.This device was associated with an increased blood glucose on an unknown date and decreased blood glucose on a separate unspecified date in (b)(6) 2018.
 
Event Description
(b)(4).This spontaneous case, reported by a consumer who contacted the company to report adverse events and product complaints (pc), concerned a (b)(6) (at the time of initial report) female patient of an unspecified origin.Medical history included diabetes since 2014.Concomitant medication included insulin glargine for an unknown indication.The patient received insulin lispro (rdna origin) (humalog, 100 u/ml) through a cartridge via a reusable pen humapen luxura half dose (hd) at an unknown dose and frequency via an unknown route of administration for the treatment of an unknown indication, beginning on an unknown date.On an unknown date, after starting insulin lispro treatment, her blood sugars was over 2000 (units and reference range not provided) and she went to the hospital.The event blood glucose increased was considered as serious due to medical significance reason.Her a1c (glycosylated hemoglobin) was over 10 (units and reference range not provided).On an unknown date, when she came back from school, her blood glucose was 530.Sometime in (b)(6) 2018, her blood glucose dropped to 40 and she was given so much of juice, (b)(6) and candy so that her blood glucose should came up.The event blood glucose decreased was considered as serious due to medical significance reason.Also, her two out of four cartridges were broken in the box.She received the box from pharmacy on (b)(6) 2018 and the box was sealed.Her mother opened the seal and the box had only four cartridges instead of five.The top part of the cartridge where the red septum was and the glass was broken and missing.(pc# for cartridge (b)(4), lot# c745492d; (b)(4), lot# c787549a; (b)(4), lot# unknown; (b)(4), lot# c815601c).Information regarding corrective treatment for remaining events and outcome of all the events was not provided.Insulin lispro treatment was continued.The operator of the humapen luxura hd was unknown and his/ her training status was not provided.The humapen luxura hd general duration of use and the suspect humapen luxura hd device duration of use were not reported.The actions taken with the suspect humapen luxura hd was not provided and its return was expected.The reporting consumer did not provide any opinion of relatedness between events and insulin lispro and humapen luxura hd.Edit 25may2018: updated medwatch and european and canadian (eu/ca) fields for expedited device reporting.No new information added.Edit 01jun2018: (b)(4) for the humapen luxura half-dose device was added for expedited device reporting.Edit 01jun2018: updated medwatch fields for expedited device reporting.No new information added.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
HUMAPEN LUXURA HALF-DOSE PEN
Type of Device
FOR TREATMENT PURPOSES
Manufacturer (Section D)
ELI LILLY AND COMPANY
lilly corporate center
indianapolis IN 46285
Manufacturer (Section G)
PHILLIPS-MEDISIZE CORPORATION
medical device manufacturing
415 red cedar street
menomonie WI 54751
Manufacturer Contact
chris davis
lilly corporate center
indianapolis, IN 46285
3174334585
MDR Report Key7566644
MDR Text Key110069902
Report Number1819470-2018-00098
Device Sequence Number1
Product Code FMF
UDI-Device Identifier00300029673019
UDI-Public00300029673019
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K063151
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type consumer
Reporter Occupation Other
Type of Report Initial
Report Date 06/04/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received06/04/2018
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Other
Device Model NumberMS9673A
Was Device Available for Evaluation? Yes
Is the Reporter a Health Professional? No
Was the Report Sent to FDA? No
Date Manufacturer Received05/17/2018
Was Device Evaluated by Manufacturer? No
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other;
Patient Age13 YR
-
-